- Home
- ADTX
ADTX
Aditxt Inc.
as of 02-25-2026 4:00pm EST
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 1.1M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 161.6K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -1605.17 | EPS Growth: | -2731.72 |
| 52 Week Low/High: | $0.02 - $12.92 | Next Earning Date: | 01-01-0001 |
| Revenue: | $133,985 | Revenue Growth: | -79.23% |
| Revenue Growth (this year): | 15768.94% | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.00 | Index: | N/A |
| Free Cash Flow: | -16776528.0 | FCF Growth: | N/A |
AI-Powered ADTX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare ADTX vs Leading Stocks
See how ADTX stacks up against similar companies in the market
Head-to-Head Comparisons
More Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ADTX Aditxt Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.